As we move away from a system of external development grants that help us maintain our HIV models to a system where our returns on investment support the work that we do, there’s a concern that there will be some slimming down of services that get patients in to our practice, explained Stella A. Safo, MD, assistant professor of Medicine at the Icahn School of Medicine at Mount Sinai.
As we move away from a system of external development grants that help us maintain our HIV models to a system where our returns on investment support the work that we do, there’s a concern that there will be some slimming down of services that get patients in to our practice, explained Stella A. Safo, MD, assistant professor of Medicine at the Icahn School of Medicine at Mount Sinai.
Transcript
What are the biggest management challenges that we’re still facing when trying to treat patients with HIV?
HIV has made a tremendous amount of progress from being a disease that was a death sentence and hugely stigmatized to now being something that people manage like a chronic illness like diabetes. But I think one of the biggest management problems that we face is that the HIV care models that we use are based on a lot of funding. We’ve had a lot of philanthropic funding that supports the care models For example, in my practice, I have a massage therapist that takes care of my patients because we got a grant that allows that.
As we move away from a system of external development grants kind of helping us maintain our HIV models to a system where our [ROIs] returns on investment support the work that we do, there’s a concern that there will be some slimming down of those services and those services are actually some of the things that help bring patients into our practices. We know with population health and value-based care delivery that it’s all about getting your patients to come in. In HIV, because of the stigma and all of the other issues, we work really hard on getting our patients to come in, and one of the ways we do that is through nontraditional services like massage therapy, reiki, etc. So, our big management question is going to be what happens to our ability to continue that work when the financial models behind that change going down the line.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Sarcoma Care: Biomarker Advancements Shape the Future
October 24th 2024At the regional Institute for Value-Based Medicine® event in Boston, Vinayak Venkataraman, MD, medical oncologist at Dana-Farber Cancer Institute and Harvard Medical School, was a panelist for the discussion, “Recent Advancements in Identifying Predictive Biomarkers for Sarcomas."
Read More
Recognizing Symptoms of Myeloproliferative Neoplasms and Clinical Trial Challenges
October 24th 2024There can be a delay in diagnosis of myeloproliferative neoplasms as the symptoms of the diseases can be variable and common, such as fatigue, migraines, and difficulty concentrating, explained Ruben Mesa, MD, of Atrium Health.
Read More